NRx Pharmaceuticals (NRXP) Competitors $3.21 -0.06 (-1.83%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$3.30 +0.09 (+2.65%) As of 06:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXP vs. ESPR, BTMD, NBTX, PRQR, SLRN, TVGN, MNPR, SXTC, SLS, and EDITShould you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include Esperion Therapeutics (ESPR), biote (BTMD), Nanobiotix (NBTX), ProQR Therapeutics (PRQR), Acelyrin (SLRN), Semper Paratus Acquisition (TVGN), Monopar Therapeutics (MNPR), China SXT Pharmaceuticals (SXTC), SELLAS Life Sciences Group (SLS), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. NRx Pharmaceuticals vs. Its Competitors Esperion Therapeutics biote Nanobiotix ProQR Therapeutics Acelyrin Semper Paratus Acquisition Monopar Therapeutics China SXT Pharmaceuticals SELLAS Life Sciences Group Editas Medicine NRx Pharmaceuticals (NASDAQ:NRXP) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Which has more risk and volatility, NRXP or ESPR? NRx Pharmaceuticals has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Does the media prefer NRXP or ESPR? In the previous week, Esperion Therapeutics had 4 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 9 mentions for Esperion Therapeutics and 5 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 1.08 beat Esperion Therapeutics' score of 0.34 indicating that NRx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is NRXP or ESPR more profitable? NRx Pharmaceuticals has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -59.03%. NRx Pharmaceuticals' return on equity of 0.00% beat Esperion Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NRx PharmaceuticalsN/A N/A -355.00% Esperion Therapeutics -59.03%-0.91%-29.47% Do analysts rate NRXP or ESPR? NRx Pharmaceuticals currently has a consensus price target of $28.50, suggesting a potential upside of 787.85%. Esperion Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 488.24%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than Esperion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Esperion Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do institutionals and insiders have more ownership in NRXP or ESPR? 4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 19.0% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable valuation and earnings, NRXP or ESPR? NRx Pharmaceuticals has higher earnings, but lower revenue than Esperion Therapeutics. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNRx PharmaceuticalsN/AN/A-$25.13M-$2.01-1.60Esperion Therapeutics$332.31M0.71-$51.74M-$0.80-1.49 SummaryNRx Pharmaceuticals beats Esperion Therapeutics on 9 of the 15 factors compared between the two stocks. Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXP vs. The Competition Export to ExcelMetricNRx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.50M$2.42B$5.54B$9.08BDividend YieldN/A1.81%5.06%4.03%P/E Ratio-1.609.2228.2820.33Price / SalesN/A648.96411.8596.42Price / CashN/A22.3426.2427.98Price / Book-2.174.638.125.50Net Income-$25.13M$30.99M$3.19B$250.38M7 Day Performance-4.75%6.64%3.68%2.19%1 Month Performance-6.69%22.22%7.69%10.92%1 Year Performance29.44%-3.88%29.35%16.41% NRx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXPNRx Pharmaceuticals2.7969 of 5 stars$3.21-1.8%$28.50+787.9%+29.4%$55.50MN/A-1.602Positive NewsESPREsperion Therapeutics3.9738 of 5 stars$1.11-5.1%$7.00+530.6%-52.6%$231.89M$332.31M-1.39200News CoverageAnalyst RevisionBTMDbiote3.2768 of 5 stars$3.99-5.5%$8.00+100.5%-49.6%$230.88M$199.38M6.54194Positive NewsNBTXNanobiotix2.7998 of 5 stars$4.75-2.5%$8.00+68.6%-7.2%$229.54M$39.18M0.00100PRQRProQR Therapeutics2.5407 of 5 stars$2.14-1.8%$8.00+273.8%+25.4%$229.36M$20.46M-6.11180Analyst ForecastSLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135TVGNSemper Paratus Acquisition4.0203 of 5 stars$1.20-3.2%$10.00+733.3%+66.4%$228.03MN/A0.003Gap DownMNPRMonopar Therapeutics2.1826 of 5 stars$37.20+2.6%$60.00+61.3%+936.1%$221.68MN/A-10.6910SXTCChina SXT Pharmaceuticals0.9337 of 5 stars$1.69-10.1%N/A-82.9%$218.13M$1.93M0.0090Gap DownSLSSELLAS Life Sciences Group0.3308 of 5 stars$2.17flatN/A+58.6%$216.52M$1M-5.7110High Trading VolumeEDITEditas Medicine4.2461 of 5 stars$2.54-1.2%$4.70+85.0%-48.0%$215.14M$32.31M-0.84230 Related Companies and Tools Related Companies Esperion Therapeutics Alternatives biote Alternatives Nanobiotix Alternatives ProQR Therapeutics Alternatives Acelyrin Alternatives Semper Paratus Acquisition Alternatives Monopar Therapeutics Alternatives China SXT Pharmaceuticals Alternatives SELLAS Life Sciences Group Alternatives Editas Medicine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXP) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRXP Stock Alerts